Momenta Pharmaceuticals, Inc. (MNTA)

[flatlander_60048]

I think you are dreaming if you think either of the two factors you mentioned would sway Teva to retract its ANDA. Fact of the matter is that their ongoing investment is minimal and the admission that they are not making progress with the approval would further reinforce the impression that MNTAs technology is far superior. This could be damaging in terms of the perceptions of copaxones vulnerability.

The majority of the analysts that follow Teva have projected approval of t-lovenox by the end of 2011. If this does not happen and the estimates get pushed back further, I believe that the overhang on MNTA will begin to lift by years end.


With regard to the technical analysis, it appears that we have reached the point were it works until it does not work anymore, and you are now searcing for a new pattern. Perhaps the patent trial will provide an impetus for further gains.

FL